Sunitinib
Jump to navigation
Jump to search
Sunitinib (marketed with the brand name Sutent) is a tyrosine kinase inhibitor used to treat renal cell carcinoma (RCC).
In RCC acts on:[1]
- VEGF.
- PDGFbeta.